Please login to the form below
ViroPharma
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of ViroPharma's 2013 immunology sales performance.
Nabriva Therapeutics appoints chief medical officer
Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
Merck says drug for CMV in transplant patients hits targets
phase III testing that it acquired along with ViroPharma in 2013.
FDA grants fast track designation to Shire’s Cinryze
At the end of 2013, Shire signed a deal with US company Viropharma for around $4.2bn which gave the company rights to Cinryze.
Pharma deals in August 2015
indication]. Interestingly, the right to make the Meritage acquisition came via the purchase of ViroPharma.
Medius Deal Watch table for February 2015
Turkey. † US. †† Financial details source - Viropharma's 2013 Consolidated Financial Statement.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
-
Head of Health Psychology, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- Scientists discover new approach to treat brain tumours
- Almirall and Inserm Transfert to develop innovative vitiligo treatments
- EIT Health and Biogen announce winners of first ‘neurotechprize’
- Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure
- Assessing the value of interim analyses in clinical trials
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Live Webinar: Engaging Patients "Just-In-Time" with Machine Learning
- Almirall and Inserm Transfert to develop innovative vitiligo treatments
- Recognising HIV Vaccine Awareness Day
- AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- Roche shares new positive Ocrevus data for MS patients
- How scientific storytelling can help Pharma cut through the noise
- How patient experience mapping can improve patient recruitment
- FDA approves Alexion’s Ultomiris for generalised myasthenia gravis
- Getting patients to engage with clinical trials
- Mapping patient pathways – with a focus on patient-centricity
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
- Serious about sustainability?
- Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
